SD Biosensor Targets KRW 1.2 Trillion in Consolidated Revenue by 2029
Bitget2026/10/28 10:03- SD Biosensor targets 2029 consolidated revenue of KRW 1.2 trillion with a 13% operating margin under its corporate value enhancement plan.
- Other targets include EBITDA of KRW 250 billion and a price-to-book ratio of 1.0 times.
- Molecular diagnostics expansion will focus on M10 installations, broader testing menus and European IVDR compliance and US FDA clearance to grow recurring reagent sales.
- Growth initiatives include expanding international procurement sales for rapid diagnostics and entering global automated immunodiagnostics markets with STANDARD i.
- Shareholder returns will include continued dividends and treasury share cancellations during 2026–2028, with interim dividends planned if earnings improve.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
